Published On: Wed, Jul 8th, 2015

Biopharma co Chiasma updates Nasdaq IPO terms

The company will raise $80 million to build a marketing network for its oral acromegaly treatment.

Chiasma-Roni Mamluk


Biopharmaceutical company Chiasma has updated the terms of its Nasdaq IPO with the US Securities and Exchange Commission (SEC). The company, which recently submitted a request for marketing approval of its drug for treatment of acromegaly, a diseas stemming from excessive hormone growth, will raise $80 million, and up to $92 million if the underwriters options are realized. Barclays Capital and Cowen & Co. are leading the offering with William Blair and Oppenheimer as the secondary underwriters… READ MORE


GLOBES logo-eng (1) Published by Globes [online], Israel business news –



Chiasma Raises $70 Million to Advance Its Endocrine Disease Medication

Israeli-American privately held biomed company Chiasma announced the closing of a $70 million Series E financing round. The company will use the new capital to build its sales and marketing capabilities and prepare More…

Oral Meds

Gil Tanenbaum On Saturday, January 3rd, 2015

Israeli-American Biomed Firm Chiasma Raises $33.8 Million to Continue Development of Oral Meds

Israeli biomed company Chiasma has raised $33.8 million out of a planned total $56.3 million round of fundraising. It plans to use the infusion of new capital to continue the development of its oral octreotide. MPM More…


Gali Weinreb On Wednesday, August 6th, 2014

Roche Cancels $600 Million Chiasma Deal

Chiasma: The product is good. This was a strategic decision by Roche to be less involved in hormone-based drugs. – Roche AG (SWX: ROG) has notified Israeli startup Chiasma that it has cancelled a commercial More…

Read more about: , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems